Compare PYPD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PYPD | NYXH |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Israel | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0M | 91.6M |
| IPO Year | 2014 | 2021 |
| Metric | PYPD | NYXH |
|---|---|---|
| Price | $6.51 | $0.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $11.50 | $2.80 |
| AVG Volume (30 Days) | 193.8K | ★ 214.4K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $234.49 |
| Revenue Next Year | N/A | $98.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $0.80 |
| 52 Week High | $7.15 | $5.39 |
| Indicator | PYPD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 33.70 |
| Support Level | $4.26 | $0.80 |
| Resistance Level | $7.15 | $0.97 |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 62.63 | 45.97 |
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.